Genome-wide analysis of esophageal adenocarcinoma yields specific copy number aberrations that correlate with prognosis

Genes Chromosomes and Cancer

Volumn 53, Issue 4, 2014, Pages 324-338

  Frankel, Adam ^a   Armour, Nicola ^a   Nancarrow, Derek ^b   Krause, Lutz ^b   Hayward, Nicholas ^b   Lampe, Guy ^c   Smithers, B Mark ^a   Barbour, Andrew ^a  

^a UNIVERSITY OF QUEENSLAND   (Australia)

^b QIMR BERGHOFER MEDICAL RESEARCH INSTITUTE   (Australia)

^c PRINCESS ALEXANDRA HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; DNA COPY NUMBER VARIATIONS; ESOPHAGEAL NEOPLASMS; FEMALE; GENOME-WIDE ASSOCIATION STUDY; HUMANS; MALE; MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE; PROGNOSIS;

EID: 84894043638     PISSN: 10452257     EISSN: 10982264     Source Type: Journal    
DOI: 10.1002/gcc.22143     Document Type: Article

References (51)

1. Albrecht B, Hausmann M, Zitzelsberger H, Stein H, Siewert JR, Hopt U, Langer R, Hofler H, Werner M, Walch A. 2004. Array-based comparative genomic hybridization for the detection of DNA sequence copy number changes in Barrett's adenocarcinoma. J Pathol 203:780-788.
2. Bandla S, Pennathur A, Luketich JD, Beer DG, Lin L, Bass AJ, Godfrey TE, Litle VR. 2012. Comparative genomics of esophageal adenocarcinoma and squamous cell carcinoma. Ann Thorac Surg 93:1101-1106.
3. Beer DG, Kardia SL, Huang CC, Giordano TJ, Levin AM, Misek DE, Lin L, Chen G, Gharib TG, Thomas DG, Lizyness ML, Kuick R, Hayasaka S, Taylor JM, Iannettoni MD, Orringer MB, Hanash S. 2002. Gene-expression profiles predict survival of patients with lung adenocarcinoma. Nat Med 8:816-824.
4. Beroukhim R, Getz G, Nghiemphu L, Barretina J, Hsueh T, Linhart D, Vivanco I, Lee JC, Huang JH, Alexander S, Du J, Kau T, Thomas RK, Shah K, Soto H, Perner S, Prensner J, Debiasi RM, Demichelis F, Hatton C, Rubin MA, Garraway LA, Nelson SF, Liau L, Mischel PS, Cloughesy TF, Meyerson M, Golub TA, Lander ES, Mellinghoff IK, Sellers WR. 2007. Assessing the significance of chromosomal aberrations in cancer: Methodology and application to glioma. Proc Natl Acad Sci USA 104:20007-20012.
5. Biankin AV, Biankin AV, Waddell N, Kassahn KS, Gingras MC, Muthuswamy LB, Johns AL, Miller DK, Wilson PJ, Patch AM, Wu J, Chang DK, Cowley MJ, Gardiner BB, Song S, Harliwong I, Idrisoglu S, Nourse C, Nourbakhsh E, Manning S, Wani S, Gongora M, Pajic M, Scarlett CJ, Gill AJ, Pinho AV, Rooman I, Anderson M, Holmes O, Leonard C, Taylor D, Wood S, Xu Q, Nones K, Fink JL, Christ A, Bruxner T, Cloonan N, Kolle G, Newell F, Pinese M, Mead RS, Humphris JL, Kaplan W, Jones MD, Colvin EK, Nagrial AM, Humphrey ES, Chou A, Chin VT, Chantrill LA, Mawson A, Samra JS, Kench JG, Lovell JA, Daly RJ, Merrett ND, Toon C, Epari K, Nguyen NQ, Barbour A, Zeps N; Australian Pancreatic Cancer Genome Initiative, Kakkar N, Zhao F, Wu YQ, Wang M, Muzny DM, Fisher WE, Brunicardi FC, Hodges SE, Reid JG, Drummond J, Chang K, Han Y, Lewis LR, Dinh H, Buhay CJ, Beck T, Timms L, Sam M, Begley K, Brown A, Pai D, Panchal A, Buchner N, De Borja R, Denroche RE, Yung CK, Serra S, Onetto N, Mukhopadhyay D, Tsao MS, Shaw PA, Petersen GM, Gallinger S, Hruban RH, Maitra A, Iacobuzio-Donahue CA, Schulick RD, Wolfgang CL, Morgan RA, Lawlor RT, Capelli P, Corbo V, Scardoni M, Tortora G, Tempero MA, Mann KM, Jenkins NA, Perez-Mancera PA, Adams DJ, Largaespada DA, Wessels LF, Rust AG, Stein LD, Tuveson DA, Copeland NG, Musgrove EA, Scarpa A, Eshleman JR, Hudson TJ, Sutherland RL, Wheeler DA, Pearson JV, McPherson JD, Gibbs RA, Grimmond SM. 2012. Pancreatic cancer genomes reveal aberrations in axon guidance pathway genes. Nature 491:399-405.
6. Blazeby JM, Farndon JR, Donovan J, Alderson D. 2000. A prospective longitudinal study examining the quality of life of patients with esophageal carcinoma. Cancer 88:1781-1787.
7. Brien TP, Odze RD, Sheehan CE, McKenna BJ, Ross JS. 2000. HER-2/neu gene amplification by FISH predicts poor survival in Barrett's esophagus-associated adenocarcinoma. Hum Pathol 31:35-39.
8. Deng N, Goh LK, Wang H, Das K, Tao J, Tan IB, Zhang S, Lee M, Wu J, Lim KH, Lei Z, Goh G, Lim Q-Y, Tan AL-K, Sin Poh DY, Riahi S, Bell S, Shi MM, Linnartz R, Zhu F, Yeoh KG, Toh HC, Yong WP, Cheong HC, Rha SY, Boussioutas A, Grabsch H, Rozen S, Tan P. 2012. A comprehensive survey of genomic alterations in gastric cancer reveals systematic patterns of molecular exclusivity and co-occurrence among distinct therapeutic targets. Gut 61:673-684.
9. Dulak AM, Schumacher S, van Lieshout J, Imamura Y, Fox C, Shim B, Ramos A, Saksena G, Baca S, Baselga J, Tabernero J, Barretina J, Enzinger P, Corso G, Roviello F, Lin L, Bandla S, Luketich J, Pennathur A, Meyerson M, Ogino S, Shivdasani RA, Beer DG, Godfrey TE, Beroukhim R, Bass AJ. 2012. Gastrointestinal adenocarcinomas of the esophagus, stomach and colon exhibit distinct patterns of genome instability and oncogenesis. Cancer Res 72:4383-4393.
10. Dulak AM, Stojanov P, Peng S, Lawrence MS, Fox C, Stewart C, Bandla S, Imamura Y, Schumacher SE, Shefler E, McKenna A, Carter SL, Cibulskis K, Sivachenko A, Saksena G, Voet D, Ramos AH, Auclair D, Thompson K, Sougnez C, Onofrio RC, Guiducci C, Beroukhim R, Zhou Z, Lin L, Lin J, Reddy R, Chang A, Landrenau R, Pennathur A, Ogino S, Luketich JD, Golub TR, Gabriel SB, Lander ES, Beer DG, Godfrey TE, Getz G, Bass AJ. 2013. Exome and whole-genome sequencing of esophageal adenocarcinoma identifies recurrent driver events and mutational complexity. Nat Genetics 45:478-486.
11. Goh XY, Rees JR, Paterson AL, Chin SF, Marioni JC, Save V, O'Donovan M, Eijk PP, Alderson D, Ylstra B, Caldas C, Fitzgerald RC. 2011. Integrative analysis of array-comparative genomic hybridisation and matched gene expression profiling data reveals novel genes with prognostic significance in oesophageal adenocarcinoma. Gut 60:1317-1326.
12. Greenawalt DM, Duong C, Smyth GK, Ciavarella ML, Thompson NJ, Tiang T, Murray WK, Thomas RJS, Phillips WA. 2007. Gene expression profiling of esophageal cancer: Comparative analysis of Barrett's esophagus, adenocarcinoma, and squamous cell carcinoma. Int J Cancer 120:1914-1921.
13. Gu J, Ajani JA, Hawk ET, Ye Y, Lee JH, Bhutani MS, Hofstetter WL, Swisher SG, Wang KK, Wu X. 2010. Genome-wide catalogue of chromosomal aberrations in Barrett's esophagus and esophageal adenocarcinoma: A High-Density Single Nucleotide Polymorphism Array Analysis. Cancer Prev Res 3:1176-1186.
14. Hasina R, Mollberg NM, Kawada I, Mutreja K, Kanade G, Yala S, Surati M, Liu R, Li X, Zhou Y, Ferguson BD, Nallasura V, Cohen KS, Hyjek E, Mueller J, Kanteti R, El-Hashani E, Kane D, Shimada Y, Lingen MW, Husain AN, Posner MC, Waxman I, Villaflor VM, Ferguson MK, Varticovski L, Vokes EE, Gill P, Salgia R. 2012. Critical role for the receptor tyrosine kinase EPHB4 in esophageal cancers. Cancer Res 73:184-194.
15. Hirst J, Smithers BM, Gotley DC, Thomas J, Barbour A. 2011. Defining cure for esophageal cancer: Analysis of actual 5-year survivors following esophagectomy. Ann Surg Oncol 18:1766-1774.
16. Horner MJRL, Krapcho M, Neyman N, Aminou R, Howlader N, Altekruse SF, Feuer EJ, Huang L, Mariotto A, Miller BA, Lewis DR, Eisner MP, Stinchcomb DG, Edwards BK. 2009. SEER Cancer Statistics Review. Bethesda, MD: National Cancer Institute.
17. Hu Y, Bandla S, Godfrey TE, Tan D, Luketich JD, Pennathur A, Qiu X, Hicks DG, Peters JH, Zhou Z. 2011. HER2 amplification, overexpression and score criteria in esophageal adenocarcinoma. Mod Pathol 24:899-907.
18. Hughes SJ, Glover TW, Zhu XX, Kuick R, Thoraval D, Orringer MB, Beer DG, Hanash S. 1998. A novel amplicon at 8p22-23 results in overexpression of cathepsin B in esophageal adenocarcinoma. Proc Natl Acad Sci USA 95:12410-12415.
19. Imai K, Takaoka A. 2006. Comparing antibody and small-molecule therapies for cancer. Nat Rev Cancer 6:714-727.
20. Langer R, Von Rahden BH, Nahrig J, Von Weyhern C, Reiter R, Feith M, Stein HJ, Siewert JR, Hofler H, Sarbia M. 2006. Prognostic significance of expression patterns of c-erbB-2, p53, p16INK4A, p27KIP1, cyclin D1 and epidermal growth factor receptor in oesophageal adenocarcinoma: A tissue microarray study. J Clin Pathol 59:631-634.
21. Li L, Ren C, Yang G, Fattah EA, Goltsov AA, Kim SM, Lee JS, Park S, Demayo FJ, Ittmann MM, Troncoso P, Thompson TC. 2011. GLIPR1 suppresses prostate cancer development through targeted oncoprotein destruction. Cancer Res 71:7694-7704.
22. Lin L, Aggarwal S, Glover TW, Orringer MB, Hanash S, Beer DG. 2000. A minimal critical region of the 8p22-23 amplicon in esophageal adenocarcinomas defined using sequence tagged site-amplification mapping and quantitative polymerase chain reaction includes the GATA-4 gene. Cancer Res 60:1341-1347.
23. Lo KC, Bailey D, Burkhardt T, Gardina P, Turpaz Y, Cowell JK. 2008. Comprehensive analysis of loss of heterozygosity events in glioblastoma using the 100K SNP mapping arrays and comparison with copy number abnormalities defined by BAC array comparative. Genes Chromosomes Cancer 47:221-237.
24. Maniatis T, Fritsch E, Sambrook J. 1982. Molecular Cloning: A Laboratory Manual, 1st ed. Cold Spring Harbor, New York: Cold Spring Harbor Laboratory Press.
25. Mermel CH, Schumacher SE, Hill B, Meyerson ML, Beroukhim R, Getz G. 2011. GISTIC2.0 facilitates sensitive and confident localization of the targets of focal somatic copy-number alteration in human cancers. Genome Biol 12:R41.
26. Miyawaki Y, Kawachi H, Ooi A, Eishi Y, Kawano T, Inazawa J, Imoto I. 2012. Genomic copy-number alterations of MYC and FHIT genes are associated with survival in esophageal squamous-cell carcinoma. Cancer Sci 103:1558-1566.
27. Nancarrow DJ, Handoko HY, Stark MS, Whiteman DC, Hayward NK. 2007. SiDCoN: A tool to aid scoring of DNA copy number changes in SNP chip data. PLoS One 2:e1093.
28. Nancarrow DJ, Handoko HY, Smithers BM, Gotley DC, Drew PA, Watson DI, Clouston AD, Hayward NK, Whiteman DC, Australian Canc Study Study D. 2008. Genome-wide copy number analysis in esophageal adenocarcinoma using high-density single-nucleotide polymorphism arrays. Cancer Res 68:4163-4172.
29. Olshen AB, Venkatraman ES, Lucito R, Wigler M. 2004. Circular binary segmentation for the analysis of array-based DNA copy number data. Biostatistics 5:557-572.
30. Ong CAJ, Lao-Sirieix P, Fitzgerald RC. 2010. Biomarkers in Barrett's esophagus and esophageal adenocarcinoma: Predictors of progression and prognosis. World J Gastroenterol 16:5669-5681.
31. Pasello G, Agata S, Bonaldi L, Corradin A, Montagna M, Zamarchi R, Parenti A, Cagol M, Zaninotto G, Ruol A, Ancona E, Amadori A, Saggioro D. 2009. DNA copy number alterations correlate with survival of esophageal adenocarcinoma patients. Mod Pathol 22:58-65.
32. Paulson TG, Maley CC, Li XH, Li H, Sanchez CA, Chao DL, Odze RD, Vaughan TL, Blount PL, Reid BJ. 2009. Chromosomal instability and copy number alterations in Barrett's esophagus and esophageal adenocarcinoma. Clin Cancer Res 15:3305-3314.
33. Peiffer DA, Le JM, Steemers FJ, Chang WH, Jenniges T, Garcia F, Haden K, Li JZ, Shaw CA, Belmont J, Cheung SW, Shen RM, Barker DL, Gunderson KL. 2006. High-resolution genomic profiling of chromosomal aberrations using Infinium whole-genome genotyping. Genome Res 16:1136-1148.
34. Pohl H, Welch HG. 2005. The role of overdiagnosis and reclassification in the marked increase of esophageal adenocarcinoma incidence. J Natl Cancer Inst 97:142-146.
35. Polkowski W, van Sandick JW, Offerhaus GJ, ten Kate FJ, Mulder J, Obertop H, van Lanschot JJ. 1999. Prognostic value of Lauren classification and c-erbB-2 oncogene overexpression in adenocarcinoma of the esophagus and gastroesophageal junction. Ann Surg Oncol 6:290-297.
36. Rice TW, Blackstone EH, Rusch VW. 2010. 7th edition of the AJCC cancer staging manual: Esophagus and esophagogastric junction. Ann Surg Oncol 17:1721-1724.
37. Riegman PHJ, Vissers KJ, Alers JC, Geelen E, Hop WCJ, Tilanus HW, van Dekken H. 2001. Genomic alterations in malignant transformation of Barrett's esophagus. Cancer Res 61:3164-3170.
38. Schoppmann SF, Jesch B, Friedrich J, Wrba F, Schultheis A, Pluschnig U, Maresch J, Zacherl J, Hejna M, Birner P. 2010. Expression of Her-2 in carcinomas of the esophagus. Am J Surg Pathol 34:1868-1873.
39. Selaru FM, Zou T, Xu Y, Shustova V, Yin J, Mori Y, Sato F, Wang S, Olaru A, Shibata D, Greenwald BD, Krasna MJ, Abraham JM, Meltzer SJ. 2002. Global gene expression profiling in Barrett's esophagus and esophageal cancer: A comparative analysis using cDNA microarrays. Oncogene 21:475-478.
40. Sjoquist KM, Burmeister BH, Smithers BM, Zalcberg JR, Simes RJ, Barbour A, Gebski V, Australasian Gastro-Intestinal T. 2011. Survival after neoadjuvant chemotherapy or chemoradiotherapy for resectable oesophageal carcinoma: An updated meta-analysis. Lancet Oncol 12:681-692.
41. Smeets SJ, Harjes U, van Wieringen WN, Sie D, Brakenhoff RH, Meijer GA, Ylstra B. 2011. To DNA or not to DNA? That is the question, when it comes to molecular subtyping for the clinic! Clin Cancer Res 17:4959-4964.
42. Stratton MR, Campbell PJ, Futreal PA. 2009. The cancer genome. Nature 458:719-724.
43. Thompson SK, Ruszkiewicz AR, Jamieson GG, Esterman A, Watson DI, Wijnhoven BPL, Lamb PJ, Devitt PG. 2008. Improving the accuracy of TNM staging in esophageal cancer: A pathological review of resected specimens. Ann Surg Oncol 15:3447-3458.
44. Thompson SK, Sullivan TR, Davies R, Ruszkiewicz AR. 2011. HER-2/neu gene amplification in esophageal adenocarcinoma and its influence on survival. Ann Surg Oncol 18:2010-2017.
45. van de Vijver MJ, He YD, van't Veer LJ, Dai H, Hart AAM, Voskuil DW, Schreiber GJ, Peterse JL, Roberts C, Marton MJ, Parrish M, Atsma D, Witteveen A, Glas A, Delahaye L, van der Velde T, Bartelink H, Rodenhuis S, Rutgers ET, Friend SH, Bernards R. 2002. A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med 347:1999-2009.
46. Varis A, Puolakkainen P, Savolainen H, Kokkola A, Salo J, Nieminen O, Nordling S, Knuutila S. 2001. DNA copy number profiling in esophageal Barrett adenocarcinoma: Comparison with gastric adenocarcinoma and esophageal squamous cell carcinoma. Cancer Genet Cytogenet 127:53-58.
47. Walch AK, Zitzelsberger HF, Bruch J, Keller G, Angermeier D, Aubele MM, Mueller J, Stein H, Braselmann H, Siewert JR, Hofler H, Werner M. 2000. Chromosomal imbalances in Barrett's adenocarcinoma and the metaplasia-dysplasia-carcinoma sequence. Am J Pathol 156:555-566.
48. Wang Y, Jatkoe T, Zhang Y, Mutch MG, Talantov D, Jiang J, McLeod HL, Atkins D. 2004. Gene expression profiles and molecular markers to predict recurrence of Dukes' B colon cancer. J Clin Oncol 22:1564-1571.
49. Weiss MM, Kuipers EJ, Hermsen MA, van Grieken NC, Offerhaus J, Baak JP, Meuwissen SG, Meijer GA. 2003. Barrett's adenocarcinomas resemble adenocarcinomas of the gastric cardia in terms of chromosomal copy number changes, but relate to squamous cell carcinomas of the distal oesophagus with respect to the presence of high-level amplifications. J Pathol 199:157-165.
50. Wiech T, Nikolopoulos E, Weis R, Langer R, Bartholome K, Timmer J, Walch AK, Hofler H, Werner M. 2009. Genome-wide analysis of genetic alterations in Barrett's adenocarcinoma using single nucleotide polymorphism arrays. Lab Invest 89:385-397.
51. Wu D, Ozaki T, Yoshihara Y, Kubo N, Nakagawara A. 2012. Runt-related transcription factor 1 (RUNX1) stimulates tumor suppressor p53 in response to DNA damage through complex formation and acetylation. J Biol Chem 288:1353-1364.